---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000141"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:08:01.035632+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing

## Summary
- Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.
- Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.
- Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.
- CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair.

## SEC filing metadata
- accession: 0001650664-24-000141
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/0001650664-24-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000141
- JSON: https://secwatch.observer/filing/0001650664-24-000141.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.